Mavyret (glecaprevir/pibrentasvir) is a prescription drug that’s used to treat hepatitis C. Mavyret can cause side effects that range from mild to serious. Examples ...

Mavyret is an antiviral drug prescribed to treat hepatitis C (HCV). It comes as oral tablets and pellets. Mavyret works by stopping HCV from multiplying, which can cure this condition. Mavyret is a ...

Mavyret (glecaprevir/pibrentasvir) is a prescription brand-name medication. The Food and Drug Administration (FDA) has approved it to treat certain forms of hepatitis ...

Editor's Note: This headline and story have been updated to clarify that the FDA approval was for an expanded indication to treat acute HCV. Glecaprevir, one of the two DAAs in Mavyret, was Discovered ...

The Dosage and Administration section has been revised to state that Mavyret is recommended for 12 weeks in liver or kidney transplant recipients. The Food and Drug Administration (FDA) has approved ...

Get set for even more competition in the hepatitis C space. AbbVie’s Mavyret picked up FDA approval on Thursday as an 8-week treatment regardless of genotype, becoming the first such drug with the ...

AbbVie’s hepatitis C blockbuster Mavyret could soon also be an eight-week treatment for patients with compensated cirrhosis, thanks to positive new phase 3b data. That would give it more firepower as ...

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion. The approval ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Mavyret demonstrated 97% sustained virologic response in ...

The VOYAGE-1 and VOYAGE-2 trials included HCV genotype 1, 2, 3, 4, or 6 infected patients with cirrhosis (VOYAGE-1) or compensated cirrhosis (VOYAGE-2) who were ...